Gilead Sciences announced that the China FDA has approved Sovaldi for the treatment of chronic hepatitis C virus infection.
HCV is the fourth-most commonly reported infectious disease in China, with approximately 10 million people infected (by comparison, in the U.S. it is estimated that 3-4 million people are infected).
Sovaldi is the first Gilead HCV medicine approved in China. The drug was granted marketing approval from the U.S. FDA in 2013 and the European Commission in 2014. It is approved for use in 79 other countries.
Read the press release